Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.

Despite monoclonal antibodies against CGRP pathway and gepants can be undoubtedly considered top-of-the-range treatments, there are still issues deserving to be addressed in the coming years as the risk of off-target effects as well as their economic sustainability based on the considerable migraine burden.